FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308407100> ?p ?o ?g. }

• W4308407100 abstract "<h3>Background</h3> Symbiotic microbes that colonize gut promote host immunity.¹ Cancer disrupts this homeostasis to alter microbial populations (“dysbiosis”) that suppresses anti-cancer immunity. Yet, the mechanisms of how dysbiosis suppresses anti-tumor immunity remain unclear. Group 2 innate lymphoid cells (ILC2s) are innate lymphocytes that reside in tissues including the gut, respond to the alarmin interleukin-33 (IL-33), and maintain microbial homeostasis in barrier surfaces.² ILC2s also activate anti-tumor immunity in multiple cancers.^3-7 Yet, links between dysbiosis, ILC2s, and anti-tumor immunity, remain unexplored. <h3>Methods</h3> To investigate if cancer dysbiosis modulates ILC2s, we examined dysbiosis in pancreatic ductal adenocarcinoma (PDAC), where dysbiosis correlates with fewer intratumoral T cells and worse survival.^8,9 PDAC is also infiltrated by anti-tumor ILC2s.⁷ Briefly, we analyzed dysbiosis by 16S-rRNA gene sequencing in fecal samples of PDAC mice deficient or not for ILC2s or <i>IL33</i>. To study the effect of dysbiosis on ILC2s, we ablated dysbiosis using antibiotics or reconstituted it in germ-free mice, we explored ILC2s migration using parabiosis. <h3>Results</h3> We found that PDAC induced <i>Bacteroidetes</i> overgrowth, thus phenocopying PDAC dysbiosis in patients.^8,10,11 Interestingly, PDAC-dysbiosis suppressed intestinal ILC2s frequencies, as dysbiosis ablation with antibiotics increased, and fecal transplantation in germ-free mice conversely decreased intestinal ILC2 frequencies. Reciprocally, we found that ILC2 and <i>IL33-</i>deficient mice evidenced <i>Bacteroidetes</i> overgrowth at steady state, thus phenocopying the PDAC-induced dysbiosis. Interestingly, ILC2 and <i>IL33-</i>deficient mice also evidenced accelerated PDAC growth, and worse survival compared to wild-type mice (WT). Thus, PDAC-dysbiosis suppresses intestinal ILC2s that serve to maintain optimal gut homeostasis. We next investigated how dysbiosis-induced ILC2s suppression modulates tumor growth. We previously reported that IL-33 responsive ILC2s infiltrate PDAC to activate antigen-specific CD8⁺T cells.⁷ We identified these anti-tumor ILC2s as unique migratory ILC2s that traffic to tumors. We thus hypothesized dysbiosis may promote tumors by modulating ILC2s migration from the intestine reservoir. Consistently, in parabiotic mice, recombinant IL-33 (rIL-33) induced ILC2s to migrate hematogenously to PDACs in different tissues, and antibiotic ablation of dysbiosis lowered donor-derived ILC2s frequencies in recipient blood and intestine. Thus, dysbiosis modulates anti-tumor ILC2s frequencies in circulation and gut reservoirs. Interestingly, in WT PDAC mice, rIL-33 expanded intestinal ILC2s, restored microbiome composition, increased tumor-infiltrating ILC2s, and reduced PDAC growth. <h3>Conclusions</h3> We find that cancer dysbiosis suppresses anti-tumor immunity by suppressing gut-derived ILC2s. Moreover, rIL-33 expands ILC2s in the gut and circulation to restore dysbiosis-suppressed ILC2s and controls PDAC. We thus introduce the therapeutic potential of IL33-based immunotherapies to reverse the dysbiotic state in cancer. <h3>References</h3> Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. <i>Nature.</i> 2016;<b>535</b>(7610):65–74. Monticelli LA, Osborne LC, Noti M, Tran S V, Zaiss DMW, Artis D. IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. <i>Proc Natl Acad Sci U S A.</i> 2015;<b>112</b>(34):10762–7. Ikutani M, Yanagibashi T, Ogasawara M, Tsuneyama K, Yamamoto S, Hattori Y, <i>et al</i>. Identification of Innate IL-5–Producing Cells and Their Role in Lung Eosinophil Regulation and Antitumor Immunity. <i>J Immunol</i>. 2012 Jan 15;<b>188</b>(2):703–13. Kim J, Kim W, Moon UJ, Kim HJ, Choi H-J, Sin J-I, <i>et al</i>. Intratumorally Establishing Type 2 Innate Lymphoid Cells Blocks Tumor Growth. <i>J Immunol</i>. 2016;<b>196</b>(5):2410–23. Saranchova I, Han J, Zaman R, Arora H, Huang H, Fenninger F, <i>et al</i>. Type 2 innate lymphocytes actuate immunity against tumours and limit cancer metastasis. <i>Sci Rep.</i> 2018;<b>8</b>(1). Jacquelot N, Seillet C, Wang M, Pizzolla A, Liao Y, Hediyeh-zadeh S, <i>et al</i>. Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. <i>Nat Immunol [Internet].</i> 2021;<b>22</b>(7):851–64. Available from: http://dx.doi.org/10.1038/s41590-021-00943-z Moral JA, Leung J, Rojas LA, Ruan J, Zhao J, Sethna Z, <i>et al</i>. ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. <i>Nature [Internet].</i> 2020;<b>579</b>(7797):130–5. Available from: http://dx.doi.org/10.1038/s41586-020-2015-4 Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, <i>et al</i>. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. <i>Cell [Internet].</i> 2019;<b>178</b>(4):795-806.e12. Available from: https://doi.org/10.1016/j.cell.2019.07.008 Pushalkar S, Hundeyin M, Daley D, Zambirinis CP, Kurz E, Mishra A, <i>et al</i>. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. <i>Cancer Discov</i>. 2018;<b>8</b>(4):403–16. Half E, Keren N, Reshef L, Dorfman T, Lachter I, Kluger Y, <i>et al</i>. Fecal microbiome signatures of pancreatic cancer patients. <i>Sci Rep.</i> 2019;<b>9</b>(1):1–12. Ren Z, Jiang J, Xie H, Li A, Lu H, Xu S, <i>et al</i>. Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China. <i>Oncotarget</i>. 2017;<b>8</b>(56):95176–91." @default.
• W4308407100 created "2022-11-11" @default.
• W4308407100 creator A5014776317 @default.
• W4308407100 creator A5023146934 @default.
• W4308407100 creator A5030498611 @default.
• W4308407100 creator A5058857144 @default.
• W4308407100 creator A5060095341 @default.
• W4308407100 creator A5060380153 @default.
• W4308407100 creator A5061353361 @default.
• W4308407100 creator A5064775470 @default.
• W4308407100 creator A5072197934 @default.
• W4308407100 creator A5076427318 @default.
• W4308407100 creator A5081300102 @default.
• W4308407100 date "2022-11-01" @default.
• W4308407100 modified "2023-10-16" @default.
• W4308407100 title "1312 Gut dysbiosis suppresses anti-tumor ILC2s in pancreatic cancer" @default.
• W4308407100 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1312" @default.
• W4308407100 hasPublicationYear "2022" @default.
• W4308407100 type Work @default.
• W4308407100 citedByCount "0" @default.
• W4308407100 crossrefType "proceedings-article" @default.
• W4308407100 hasAuthorship W4308407100A5014776317 @default.
• W4308407100 hasAuthorship W4308407100A5023146934 @default.
• W4308407100 hasAuthorship W4308407100A5030498611 @default.
• W4308407100 hasAuthorship W4308407100A5058857144 @default.
• W4308407100 hasAuthorship W4308407100A5060095341 @default.
• W4308407100 hasAuthorship W4308407100A5060380153 @default.
• W4308407100 hasAuthorship W4308407100A5061353361 @default.
• W4308407100 hasAuthorship W4308407100A5064775470 @default.
• W4308407100 hasAuthorship W4308407100A5072197934 @default.
• W4308407100 hasAuthorship W4308407100A5076427318 @default.
• W4308407100 hasAuthorship W4308407100A5081300102 @default.
• W4308407100 hasBestOaLocation W43084071001 @default.
• W4308407100 hasConcept C121608353 @default.
• W4308407100 hasConcept C203014093 @default.
• W4308407100 hasConcept C2777165150 @default.
• W4308407100 hasConcept C2779341262 @default.
• W4308407100 hasConcept C47742525 @default.
• W4308407100 hasConcept C502942594 @default.
• W4308407100 hasConcept C539455810 @default.
• W4308407100 hasConcept C54355233 @default.
• W4308407100 hasConcept C86803240 @default.
• W4308407100 hasConcept C8891405 @default.
• W4308407100 hasConceptScore W4308407100C121608353 @default.
• W4308407100 hasConceptScore W4308407100C203014093 @default.
• W4308407100 hasConceptScore W4308407100C2777165150 @default.
• W4308407100 hasConceptScore W4308407100C2779341262 @default.
• W4308407100 hasConceptScore W4308407100C47742525 @default.
• W4308407100 hasConceptScore W4308407100C502942594 @default.
• W4308407100 hasConceptScore W4308407100C539455810 @default.
• W4308407100 hasConceptScore W4308407100C54355233 @default.
• W4308407100 hasConceptScore W4308407100C86803240 @default.
• W4308407100 hasConceptScore W4308407100C8891405 @default.
• W4308407100 hasLocation W43084071001 @default.
• W4308407100 hasOpenAccess W4308407100 @default.
• W4308407100 hasPrimaryLocation W43084071001 @default.
• W4308407100 hasRelatedWork W2001897420 @default.
• W4308407100 hasRelatedWork W2043455657 @default.
• W4308407100 hasRelatedWork W2103515427 @default.
• W4308407100 hasRelatedWork W2766647135 @default.
• W4308407100 hasRelatedWork W2916958262 @default.
• W4308407100 hasRelatedWork W2938430682 @default.
• W4308407100 hasRelatedWork W3008816470 @default.
• W4308407100 hasRelatedWork W3126867335 @default.
• W4308407100 hasRelatedWork W3209725662 @default.
• W4308407100 hasRelatedWork W4213389526 @default.
• W4308407100 isParatext "false" @default.
• W4308407100 isRetracted "false" @default.
• W4308407100 workType "article" @default.